PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1357962
PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1357962
Stargardt Disease Therapeuticss Market, By Drug Type (Emixustat, LBS-008, others, By Age Group (Children and Adult ), By Distribution Channel, and By Region
Global stargardt disease therapeutics market is estimated to be valued at US$ 213.5 Mn in 2023, and is expected to exhibit a CAGR of 31.7% during the forecast period (2023-2030).
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2022 | Market Size in 2023: | US$ 213.5 Mn |
| Historical Data for: | 2018 to 2021 | Forecast Period: | 2023 - 2030 |
| Forecast Period 2023 to 2030 CAGR: | 31.70% | 2030 Value Projection: | US$ 1,467.2 Mn |
Stargardt disease is a genetic condition that is caused by a tiny alteration in a single gene. It is also known as fundus flavimaculatus, and is the most common form of macular dystrophy. It affects approximately one in 10,000 people and affects both males and females. Stargardt causes a wasting of a central area of the retina called the macula. This area is eventually surrounded by a ring of white or yellow spots. An important layer of the retina, the retinal pigment epithelium (RPE), is also affected by an accumulation of 'waste' material called lipofuscin. Being diagnosed with Stargardt disease can be distressing, but with the right information and support, people can cope very well. It is important to remember that in the vast majority of cases, patients with stargardt disease do not lose all their sight. Stargardt disease usually affects central vision only. Peripheral vision is not usually affected. There is a great deal of research going on into potential treatments. Thus, introduction of such advanced treatment options in the market is expected to drive global stargardt disease therapeutics market growth over the forecast period.
Market Dynamics
The key players in the medical devices industry are focusing on the development of therapeutic drugs for various patient pool suffering from Stargardt disease. Thus, introduction of such advanced drugs in the market is expected to drive growth of the global stargardt disease therapeuticss market over the forecast period. For instance, on June 05, 2023, Alkeus Pharmaceuticals, a biopharmaceutical company, announced that the company had raised a US$ 150 million in Series B financing to support the registration and launch of gildeuretinol (ALK-001), a potential disease-modifying, precision medicine for the treatment of Stargardt disease, a leading genetic cause of blindness in children and young adults. The financing was led by Bain Capital Life Sciences, with additional participation by TCGX, Wellington Management and Sofinnova Investments.
Key features of the study:
- This report provides an in-depth analysis of the global stargardt disease therapeuticss market and provides market size (US$ Mn) and compound annual growth rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global stargardt disease therapeuticss market based on the following parameters- company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include Kubota Pharmaceutical Holdings Co., Ltd., Stargazer Pharmaceuticals Inc., Iveric Bio, Inc., Sanofi S.A., Alkeus Pharmaceuticals Inc., Astellas Pharma Inc., CHABiotech CO., Ltd, ReVision Therapeutics, Inc., Lin BioScience, Inc., Biogen Inc., Hoffmann-La Roche AG, Ocugen, Inc., Ascidian Therapeutics, Nanoscope Therapeutics Inc., Aequus Pharmaceuticals Inc., Fera Pharmaceuticals, LLC, Insmed Incorporated, Belite Bio, Inc., and SpliceBio
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- Global stargardt disease therapeuticss market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global stargardt disease therapeuticss market
Detailed Segmentation:
- Global Stargardt Disease Therapeuticss Market, By Drug Type:
- Emixustat
- LBS-008
- Others (Gildeuretinol)
- Global Stargardt Disease Therapeutics Market, By Age Group:
- Children (Below 17 Years)
- Adult (Above 17 Years)
- Global Stargardt Disease Therapeutics Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Stargardt Disease Therapeutics Market, By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
- Africa
- Company Profiles
- Kubota Pharmaceutical Holdings Co., Ltd.
- Stargazer Pharmaceuticals Inc.
- Iveric Bio, Inc.
- Sanofi S.A.
- Alkeus Pharmaceuticals Inc.
- Astellas Pharma Inc.
- CHABiotech CO., Ltd
- ReVision Therapeutics, Inc
- Lin BioScience, Inc.
- Biogen Inc.
- Hoffmann-La Roche AG
- Ocugen, Inc.
- Ascidian Therapeutics
- Nanoscope Therapeutics Inc.
- Aequus Pharmaceuticals Inc.
- Fera Pharmaceuticals, LLC
- Insmed Incorporated
- Belite Bio, Inc.
- SpliceBio
Table of Contents
1. Research Objective and Assumption
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drug Type
- Market Snippet, By Age Group
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Recent Test Launches
- Epidemiology
- Merger, Acquisition, and Collaborations
- Regulatory Scenario
- Key Developments
- PEST Analysis
- Epidemiology
4. Global Stargardt Disease Therapeutics Market - COVID-19 Impact Analysis
- Economic Impact
- COVID-19 Epidemiology
- Impact on Supply and Demand
5. Global Stargardt Disease Therapeutics Market, By Drug Type, 2018-2030, (US$ Mn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
- Emixustat
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Segment Trends
- LBS-008
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Segment Trends
- Others (Gildeuretinol)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Segment Trends
6. Global Stargardt Disease Therapeutics Market, By Age Group, 2018-2030, (US$ Mn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
- Children (Below 17 Years)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Segment Trends
- Adult (Above 17 Years)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Segment Trends
7. Global Stargardt Disease Therapeutics Market, By Distribution Channel, 2018-2030, (US$ Mn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
8. Global Stargardt Disease Therapeutics Market, By Region, 2018-2030, (US$ Mn)
- Introduction
- Market Share Analysis, By Region, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, For Region, 2018-2030
- Segment Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Mn)
- U.S.
- Canada
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Mn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Mn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Mn)
- North Africa
- Central Africa
- South Africa
9. Competitive Landscape
- Company Profiles
- Kubota Pharmaceutical Holdings Co., Ltd.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Stargazer Pharmaceuticals Inc.
- Iveric Bio, Inc.
- Sanofi S.A.
- Alkeus Pharmaceuticals Inc.
- Astellas Pharma Inc.
- CHABiotech CO., Ltd
- ReVision Therapeutics, Inc.
- Lin BioScience, Inc.
- Biogen Inc.
- F.Hoffmann-La Roche AG
- Ocugen, Inc.
- Ascidian Therapeutics
- Nanoscope Therapeutics Inc.
- Aequus Pharmaceuticals Inc.
- Fera Pharmaceuticals, LLC
- Insmed Incorporated
- Belite Bio, Inc.
- SpliceBio
10. Section
- References
- Research Methodology
- About us and Sales Contact
